01950nas a2200313   4500000000100000008004100001260001300042653001000055653002900065653001600094653002100110653001100131653001100142653001200153653000900165653001600174653001300190100001400203700001900217700001400236700001600250700001500266245006600281300001100347490000700358050003200365520122500397022001401622       1983                            d  c1983 Apr10aAdult10aClinical Trials as Topic10aClofazimine10aErythema Nodosum10aFemale10aHumans10aleprosy10aMale10aMiddle Aged10aNeuritis1 aBurte N P1 aChandorkar A G1 aMuley M P1 aBalsara J J1 aBulakh P M00aClofazimine in lepra (ENL) reaction, one year clinical trial.  a265-770 v55  aInfolep Library - available3 a<p>Twenty patients of lepromatous leprosy with lepra reaction and suspected dapsone resistance were treated with tapering doses of clofazimine. Clinical assessment was carried out every week. Bacteriological examination was carried out every six month. Fifteen patients became reaction free at the end of three months and severity and frequency of reactions was reduced in other patients. Nerve tenderness, arthralgia, nodular eruptions and all other signs and symptoms except anaesthesia showed complete recovery in fifteen patients and severity of the reactions was reduced in others. Gynaecomastia regressed in two out of three patients within nine months. In a majority of patients, the BI and MI was reduced at the end of 3 months, and further reduced after 6 months, and in one case both BI and MI became negative. Clinical and bacteriological improvement is attributed to the antibacterial effect of clofazimine while reduction in incidence of (ENL) reactions was attributed to anti-inflammatory effect of clofazimine. Regression of gynaecomastia may be due to either improvement of involvement of testes or liver or both. Apart from dyschromia clofazimine did not produce any severe side effects or toxicity.</p>  a0024-1024